These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 3076034)
21. [Extracellular matrix metalloproteinases--perspectives of their use in medicine]. Kotulska-Wolwender K; Larysz-Brysz M; Fus Z; Korczyńska I; Górka D; Lewin-Kowalik J Wiad Lek; 2002; 55(7-8):463-71. PubMed ID: 12428575 [TBL] [Abstract][Full Text] [Related]
22. [Clinical significance of present tumor markers]. Ohkura H Gan To Kagaku Ryoho; 1993 May; 20(7):843-9. PubMed ID: 7683865 [TBL] [Abstract][Full Text] [Related]
23. [The clinico-diagnostic significance of tumor markers in malignant neoplasms]. Seliuzhitskiĭ IV; Skvortsov SV; Lytsar' BN Voen Med Zh; 1993 Mar; (3):27-8. PubMed ID: 8498043 [No Abstract] [Full Text] [Related]
24. [Criteria for using tumor markers. 3: Indications and interpretation]. Fateh-Moghadam A; Stieber P Fortschr Med; 1996 Mar; 114(9):107-8. PubMed ID: 8690329 [No Abstract] [Full Text] [Related]
25. [The differential diagnostic value of enzyme examination in the blood serum and in the punctate fluid]. Ronský R; Procházka B; Volek V Z Gesamte Inn Med; 1965 Sep; 20(17):541-3. PubMed ID: 5866012 [No Abstract] [Full Text] [Related]
26. [Tumor markers: theory or reality?]. Molina R; Filella X; Ballesta AM Med Clin (Barc); 1994 Feb; 102(5):189-95. PubMed ID: 8127170 [No Abstract] [Full Text] [Related]
27. Introduction to tumor markers from A to Z. Plaut D MLO Med Lab Obs; 2004 Aug; 36(8):22, 26. PubMed ID: 15366364 [No Abstract] [Full Text] [Related]
28. [Blood serum enzymatic activity in pyelonephritis in children]. Chebotareva VD; Kulik NIa; Dadakina MA; Revunova EN Pediatr Akus Ginekol; 1978; (5):19-20. PubMed ID: 714508 [No Abstract] [Full Text] [Related]
30. Plasma enzymes in tumor-bearing rats. Kampschmidt RF; Upchurch HF; Johnson HL Cancer Res; 1966 Feb; 26(2):237-40. PubMed ID: 4285553 [No Abstract] [Full Text] [Related]
31. [Significance of cathepsin B and D in physiologic and pathologic processes]. Olszewska D; Drewa T; Makarewicz R; Drewa J; Woźniak A; Maciak R Pol Merkur Lekarski; 2001 Jan; 10(55):65-70. PubMed ID: 11320558 [TBL] [Abstract][Full Text] [Related]
32. [Role of isoenzymes among tumoral markers]. Assicot M; Bohuon C Ann Biol Clin (Paris); 1984; 42(5):329-35. PubMed ID: 6150665 [No Abstract] [Full Text] [Related]
33. [Tumor markers of childhood cancer]. Shioda Y; Kumagai MA Gan To Kagaku Ryoho; 2005 May; 32(5):699-704. PubMed ID: 15918577 [TBL] [Abstract][Full Text] [Related]
34. [Value and limitations of the use of enzymatic diagnosis in malignant neoplasms. LDH zymograms, quantitative determination of GOT, GPT, LDH and MDH in blood and pleuro-abdominal effusion fluids]. Emanuelli G; Cagetti M; Congiu P; Verzetti G; Montagnani M Quad Sclavo Diagn; 1972 Dec; 8(4):980-93. PubMed ID: 4668741 [No Abstract] [Full Text] [Related]
35. Continuous inappropriate use of serum tumour markers. Tran HA Intern Med J; 2005 Oct; 35(10):640-1; author reply 641. PubMed ID: 16207270 [No Abstract] [Full Text] [Related]
36. Biomarkers for cancer risk, early detection, and prognosis: the validation conundrum. Brenner DE; Normolle DP Cancer Epidemiol Biomarkers Prev; 2007 Oct; 16(10):1918-20. PubMed ID: 17932336 [No Abstract] [Full Text] [Related]
38. [Tumor markers as a means of cancer diagnosis--expectations and problems]. von Broen B Z Gesamte Inn Med; 1987 Jul; 42(14):377-82. PubMed ID: 3314200 [TBL] [Abstract][Full Text] [Related]
39. [Limitation of clinical usefulness of tumor marker]. Ishii M Gan To Kagaku Ryoho; 1995 Aug; 22(9):1139-45. PubMed ID: 7544963 [TBL] [Abstract][Full Text] [Related]
40. Biomarkers for the early detection of cancer: an inflammatory concept. Roy HK; Khandekar JD Arch Intern Med; 2007 Sep; 167(17):1822-4. PubMed ID: 17893302 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]